



LabCorp Dublin
6370 Wilcox Road
Dublin, OH 43016-1269

Phone: 800-282-7300

Specimen Number 341-127-9522-0		Patient ID		Control Number	Account Number 90000045	Account Phone Number 336-436-8645	Route 00
SAMPLE REPORT				Account Address			
Patient Last Name				LabCorp Test Master			
Patient First Name 503940		Patient Middle Name		Test Account			
Patient SS#		Patient Phone		3060 South Church Street			
Age (Y/M/D)		Date of Birth		Sex N		Fasting	
Patient Address				Additional Information			
				NORMAL			
Date and Time Collected 12/06/16 00:00		Date Entered 12/06/16		Date and Time Reported		Physician Name	NPI
						Physician ID	

Tests Ordered							
Factor V R2 DNA Analysis							

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

Factor V R2 DNA Analysis

FV R2 DNA Analysis Result: 01
A-A (Normal-Normal)
No factor V R2 polymorphism present.

Methodology: 01
Patient DNA was evaluated for the factor V R2 polymorphism at nucleotide 4070 using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) technology.

Interpretation: 01
While the patient does not possess this risk factor, other thrombotic risk factors may be detected through systematic clinical laboratory analysis.

Comment: 01
Simultaneous Risks: If a patient possesses two or more congenital or acquired thrombophilic risk factors, the risk of thrombosis may rise to more than the sum of the risk ratios for the individual risk factors. For instance, a combination of the factor V R2 polymorphism and the factor V Leiden mutation may confer a 16-fold increase in thrombotic risk over that conferred by the presence of an isolated heterozygous factor V Leiden mutation.

Recommendations: The factor V R2 polymorphism is an inherited characteristic. If the mutation is present, we recommend that the patient and their family consider genetic counseling to obtain additional information on inheritance and to identify other family members at risk. In the heterozygous individual married to a wild-type individual, their children have a 50% chance of inheriting this mutation. All children inherit at least one abnormal gene if the tested individual is homozygous.

Testing Characteristics: Genetic testing by PCR provides exceptionally high sensitivity and specificity. Inaccurate

SAMPLE REPORT, 503940		341-127-9522-0	Seq # 0000
------------------------------	--	-----------------------	------------

12/09/16 13:20 ET

DUPLICATE FINAL REPORT

Page 1 of 2

This document contains private and confidential health information protected by state and federal law.

©2004-16 Laboratory Corporation of America ® Holdings

If you have received this document in error, please call 800-762-4344

All Rights Reserved

DOC1 Ver: 1.49



LabCorp Dublin
6370 Wilcox Road
Dublin, OH 43016-1269

Phone: 800-282-7300

SAMPLE REPORT, 503940					Patient Name			Specimen Number 341-127-9522-0		
Account Number 90000045	Patient ID	Control Number	Date and Time Collected 12/06/16 00:00	Date Reported	Sex N	Age(Y/M/D)	Date of Birth			

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

results using PCR are limited to rare polymorphisms in primer binding sites and to misidentification of specimens by collectors or laboratory personnel. This assay detects only the factor V R2 polymorphism at nucleotide 4070 and does not measure genetic abnormalities elsewhere in the genome.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

For inquiries or genetic consultation please call Esoterix at 1-800-444-9111.

References: Castaman et al. Haematologica 2003;88:1182.
Althenc-Gelas et al. Thromb Haemost 1999;81:193. De Visser et al. Thromb Haemost 2000;83:577. Faioni EM et al. Blood 1999;94:3062. Castoldi E et al. Blood 2004;103:4173.

01	UY	Esoterix Coagulation Lab	Dir: Dorothy Adcock, MD
		8490 Upland Drive Ste 100, Englewood, CO 80112-7116	
For inquiries, the physician may contact Branch: 800-222-7566 Lab: 800-282-7300			

SAMPLE REPORT, 503940		341-127-9522-0	Seq # 0000
------------------------------	--	-----------------------	------------

12/09/16 13:20 ET

DUPLICATE FINAL REPORT

Page 2 of 2

This document contains private and confidential health information protected by state and federal law.

©2004-16 Laboratory Corporation of America ® Holdings

If you have received this document in error, please call 800-762-4344

All Rights Reserved

DOC1 Ver: 1.49



LabCorp Dublin
6370 Wilcox Road
Dublin, OH 43016-1269

Phone: 800-282-7300

Specimen Number 341-127-9523-0		Patient ID		Control Number	Account Number 90000045	Account Phone Number 336-436-8645	Route 00
SAMPLE REPORT				Account Address			
Patient Last Name				LabCorp Test Master			
Patient First Name 503940		Patient Middle Name		Test Account			
Patient SS#		Patient Phone		3060 South Church Street			
Age (Y/M/D)		Date of Birth		Burlington NC 27215			
		Sex N					
Patient Address				Additional Information			
				ABNORMAL			
Date and Time Collected 12/06/16 00:00	Date Entered 12/06/16	Date and Time Reported		Physician Name	NPI	Physician ID	

Tests Ordered							
Factor V R2 DNA Analysis							

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

Factor V R2 DNA Analysis

FV R2 DNA Analysis Result: 01

A-G (Normal-Mutant)

Positive - Heterozygous for the FV R2 polymorphism.

Methodology: 01

Patient DNA was evaluated for the factor V R2 polymorphism at nucleotide 4070 using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) technology.

Interpretation: 01

The R2 4070 polymorphism is present on one copy of the patient's factor V gene. Heterozygous factor V R2 alone is a very mild prothrombotic risk factor, with an incidence in the population of 5 - 12%. Heterozygous factor V R2 may be associated with a very mild increase in activated protein C (APC) resistance (for example, a decreased APCR ratio). The presence of the R2 polymorphism in factor V Leiden heterozygotes increases the risk of venous thrombosis 3 to 4 fold further than the increased risk from factor V Leiden alone (7-fold).

Comment: 01

Simultaneous Risks: If a patient possesses two or more congenital or acquired thrombophilic risk factors, the risk of thrombosis may rise to more than the sum of the risk ratios for the individual risk factors. For instance, a combination of the factor V R2 polymorphism and the factor V Leiden mutation may confer a 16-fold increase in thrombotic risk over that conferred by the presence of an isolated heterozygous factor V Leiden mutation.

Recommendations: The factor V R2 polymorphism is an inherited characteristic. If the mutation is present, we recommend that the patient and their family consider genetic counseling to obtain additional information on inheritance and to identify other family members at risk.

SAMPLE REPORT, 503940		341-127-9523-0	Seq # 0000
------------------------------	--	-----------------------	------------

12/09/16 13:21 ET

DUPLICATE FINAL REPORT

Page 1 of 2

This document contains private and confidential health information protected by state and federal law.

©2004-16 Laboratory Corporation of America ® Holdings

If you have received this document in error, please call 800-762-4344

All Rights Reserved

DOC1 Ver: 1.49



LabCorp Dublin
6370 Wilcox Road
Dublin, OH 43016-1269

Phone: 800-282-7300

SAMPLE REPORT, 503940					Patient Name			Specimen Number 341-127-9523-0		
Account Number 90000045	Patient ID	Control Number	Date and Time Collected 12/06/16 00:00	Date Reported	Sex N	Age(Y/M/D)	Date of Birth			

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

In the heterozygous individual married to a wild-type individual, their children have a 50% chance of inheriting this mutation. All children inherit at least one abnormal gene if the tested individual is homozygous.

Testing Characteristics: Genetic testing by PCR provides exceptionally high sensitivity and specificity. Inaccurate results using PCR are limited to rare polymorphisms in primer binding sites and to misidentification of specimens by collectors or laboratory personnel. This assay detects only the factor V R2 polymorphism at nucleotide 4070 and does not measure genetic abnormalities elsewhere in the genome.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

For inquiries or genetic consultation please call Esoterix at 1-800-444-9111.

References: Castaman et al. Haematologica 2003;88:1182. Althenc-Gelas et al. Thromb Haemost 1999;81:193. De Visser et al. Thromb Haemost 2000;83:577. Faioni EM et al. Blood 1999;94:3062. Castoldi E et al. Blood 2004;103:4173.

01	UY	Esoterix Coagulation Lab	Dir: Dorothy Adcock, MD
		8490 Upland Drive Ste 100, Englewood, CO 80112-7116	
For inquiries, the physician may contact Branch: 800-222-7566 Lab: 800-282-7300			

SAMPLE REPORT, 503940		341-127-9523-0	Seq # 0000
------------------------------	--	-----------------------	------------

12/09/16 13:21 ET

DUPLICATE FINAL REPORT

Page 2 of 2

This document contains private and confidential health information protected by state and federal law.

©2004-16 Laboratory Corporation of America ® Holdings

If you have received this document in error, please call 800-762-4344

All Rights Reserved

DOC1 Ver: 1.49